Table 13.6d

Immunosuppression Use: Antirejection Treatment from Transplant

to One Year Posttransplant, 1993 to 2002

Recipients with Heart-Lung Transplants

		Year of Transplant
		1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
Transplants		60	71	69	39	62	47	51	48	27	32
Tx with Antirejection Treatments		25	29	35	9	13	25	18	16	4	8
Antibodies	Category Usage	20.0%	17.2%	8.6%	11.1%	15.4%	20.0%	5.6%	18.8%	0.0%	0.0%
	ALG	0.0%	3.4%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	ATG/NRATG/NRATS	12.0%	6.9%	5.7%	11.1%	7.7%	16.0%	0.0%	6.3%	0.0%	0.0%
	OKT3	12.0%	6.9%	2.9%	0.0%	7.7%	0.0%	0.0%	0.0%	0.0%	0.0%
	Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.0%	4.0%	5.6%	0.0%	0.0%	0.0%
	Zenapax	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	12.5%	0.0%	0.0%
Corticosteroids	Category Usage	80.0%	86.2%	100.0%	100.0%	100.0%	92.0%	94.4%	93.8%	100.0%	100.0%
	Steroids	80.0%	86.2%	100.0%	100.0%	100.0%	92.0%	94.4%	93.8%	100.0%	100.0%
Antimetabolites	Category Usage	4.0%	3.4%	5.7%	0.0%	0.0%	4.0%	0.0%	0.0%	0.0%	0.0%
	Cytoxan	4.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	Methotrexate	0.0%	3.4%	5.7%	0.0%	0.0%	4.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 3, 2004.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.